IFRX - InflaRx N.V.
| Previous close | 4.0050 |
| Open | 4.0400 |
| Bid | 4.0700 x 900 |
| Ask | 4.0800 x 1000 |
| Day's range | 4.0200 - 4.1001 |
| 52-week range | 0.7760 - 7.2500 |
| Volume | |
| Avg. volume | 2,517,173 |
| Market cap | 251.303M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
InflaRx N.V.'s (NASDAQ:IFRX) Profit Outlook
InflaRx N.V. ( NASDAQ:IFRX ) is possibly approaching a major achievement in its business, so we would like to shine...
- Zacks
Biotech Stock Roundup: MRNA Provides Update, KALA, IFRX Surge on Regulatory News
Regulatory and pipeline updates from Moderna (MRNA) and KALA are the key highlights for the biotech sector.
- Motley Fool
Why InflaRx Stock Skyrocketed This Week
The biopharmaceutical company's near-term sales outlook has gotten a huge boost following Emergency Use Authorization for one of its drugs.
- Motley Fool
Why Shares of InflaRx Are Soaring Wednesday
Shares of InflaRx (NASDAQ: IFRX) were up 48% an hour after the market opened on Wednesday on news the company's COVID-19 therapy was receiving an Emergency Use Authorization (EUA) from the Food and Drug Administration (FDA). The healthcare stock jumped to a 52-week high of $7.25 a share in early trading after the FDA approved an EUA for Gohibic (vilobelimab), a monoclonal anti-human complement factor C5a antibody, to treat hospitalized COVID-19 patients within 48 hours of receiving oxygen through a ventilator or through a heart-lung machine. The EUA is based on the company's successful phase 3 study of the drug on 369 hospitalized patients that showed a 23.9% reduction in the mortality rate compared with placebo.
- Zacks
InflaRx (IFRX) Stock Up on FDA's EUA for COVID-19 Treatment
InflaRx (IFRX) shares gain as it receives emergency-use authorization from the FDA for Gohibic (vilobelimab) to treat COVID-19 in terminally-ill patients.
- Simply Wall St.
We're A Little Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
- Simply Wall St.
Here's Why InflaRx (NASDAQ:IFRX) Must Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
- Zacks
Here's Why InflaRx N.V. (IFRX) is a Great Momentum Stock to Buy
Does InflaRx N.V. (IFRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
- Zacks
InflaRx N.V. (IFRX) Upgraded to Buy: What Does It Mean for the Stock?
InflaRx N.V. (IFRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
